ClinicalTrials.Veeva

Menu

Evaluation of the Effect of Streptococcus Salivarius K12 Probiotic in the Treatment of Periodontitis

A

AYŞENUR ŞAHİN

Status

Completed

Conditions

Periodontitis Stage III
Probiotic

Treatments

Other: Probiotic Agent
Other: Non-Surgical Intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT06871540
INU-DHF-AS-01

Details and patient eligibility

About

Aims: The use of oral probiotics as an adjunct to the treatment of periodontal diseases is known to be beneficial in antagonizing pathogenic microflora and regulating the host immune response. The aim of this clinical study was to evaluate the clinical, microbiologic and biochemical effect of Streptococcus salivarius (S. salivarius) K12 probiotic tablet as an adjunct to scaling and root planing (SRP) treatment in stage 3 periodontitis patients.

Methods: The study included 30 systemically healthy stage 3 periodontitis patients. After non-surgical periodontal treatment, participants were randomly assigned to the test (SRP+Probiotic, n=15) or control (SRP, n=15) group. Patients in the test group used probiotic tablets once daily for 30 days. Clinical (Plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL)), microbiological (Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Prevotella intermedia, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum) and biochemical (IL-6, IL-8, IL-10) measurements were performed at baseline (before SRP), 30. and 90th days. Data were analyzed statistically.

Keywords: Microbiology, Periodontitis, Probiotics, Cytokines

Enrollment

30 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or female aged 18-60 years,
  • No systemic disease,
  • No periodontal treatment in the last 6 months,
  • No antibiotic therapy in the last 6 months,
  • Diagnosed with stage 3 periodontitis according to the 2017 periodontal disease classification

Exclusion criteria

  • Periodontal treatment within sixteen months,
  • Smoking,
  • Patients with systemic health problems such as diabetes, rheumatoid arthritis, neurological diseases, lung and kidney diseases,
  • Pregnancy or lactation,
  • Acute oral lesions or necrotizing ulcerative periodontitis.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

30 participants in 2 patient groups

Test Grubu
Active Comparator group
Treatment:
Other: Non-Surgical Intervention
Other: Probiotic Agent
Control
Other group
Treatment:
Other: Non-Surgical Intervention

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems